Belarusian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Biomedical Reports 2020-Jun

Cross-reactivity between Parietaria judaica and Parietaria officinalis in immunotherapy extracts for the treatment of allergy to Parietaria.

Перакладаць артыкулы могуць толькі зарэгістраваныя карыстальнікі
Увайсці / Зарэгістравацца
Спасылка захоўваецца ў буферы абмену
Nataly Cancelliere
Irene Iglesias
Ángel Ayuga
Ernesto Miranda

Ключавыя словы

Рэферат

Parietaria judaica and P. officinalis are the two most common subspecies of the Parietaria genus. P. judaica and P. officinalis have exhibited cross-reactivity in previous studies. P. judaica pollen is the main cause of allergy in the Mediterranean area. It has been shown that a high percentage of patients sensitized to P. judaica with allergic rhinitis (AR) have an increased risk of developing asthma. The present study aimed to confirm the cross-reactivity between P. judaica and P. officinalis and to evaluate the use of a single P. officinalis extract in patients allergic to both subspecies as a preferable option for the diagnosis and treatment of allergy in a highly pollinated area of the Spanish Mediterranean coast. The present study was a single centre, observational cross-sectional study of adult patients diagnosed with AR and/or bronchial asthma who were sensitized to Parietaria pollen. A total of 24 patients were enrolled in the study and included in the analysis. Allergovit® immunotherapy extracts were selected for the study based on the protein content (P. officinalis pollen extract). The results of an in vitro ELISA revealed that 79.1% (n=19) of the patient sera were reactive to immunotherapy extracts. ELISA inhibition assay of the IgE binding to P. officinalis demonstrated inhibition values >70% in the sera of highly reactive patients, confirming the cross-reactivity between the two Parietaria subspecies. In addition, all patients enrolled in the study exhibited double skin positivity against P. judaica and P. officinalis extracts, as assessed by the skin prick test, further supporting the in vivo reactivity between the two subspecies. The present study demonstrated that P. judaica and P. officinalis pollen extracts were highly cross-reactive, and that a unique P. officinalis pollen extract may be used for the diagnosis and immunotherapy of patients allergic to Parietaria.

Далучайцеся да нашай
старонкі ў facebook

Самая поўная база дадзеных пра лекавыя травы, падтрыманая навукай

  • Працуе на 55 мовах
  • Лячэнне травой пры падтрымцы навукі
  • Распазнаванне траў па малюнку
  • Інтэрактыўная GPS-карта - пазначце травы па месцы (хутка)
  • Чытайце навуковыя публікацыі, звязаныя з вашым пошукам
  • Шукайце лекавыя зёлкі па іх уздзеянні
  • Арганізуйце свае інтарэсы і будзьце ў курсе навінавых даследаванняў, клінічных выпрабаванняў і патэнтаў

Увядзіце сімптом альбо захворванне і прачытайце пра зёлкі, якія могуць дапамагчы, набярыце траву і паглядзіце хваробы і сімптомы, супраць якіх яна выкарыстоўваецца.
* Уся інфармацыя заснавана на апублікаваных навуковых даследаваннях

Google Play badgeApp Store badge